🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “L.” Clear

  1. Rixathon 100 mg concentrate for solution for infusion, Aplo-TCSE TCRaß+CD19+ depleto, Allogeneic peripheral blood-derived NK cells CD3- CD56+, Qarziba 4.5 mg/mL concentrate for solution for infusion, Melfalan Tillomed 50 mg polvere e solvente per soluzione iniettabile/infusione, TEPADINA 100 mg powder for concentrate for solution for infusion, Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione, Grafalon 20 mg/ml concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  2. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  3. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  4. SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  5. Silycus®

    Istituto Gentili S.r.l.

    Cushing's disease

    phase 2 small molecule active

    1 trial

  6. Sodio cloruro S.A.L.F. 0,9% solvente per uso parenterale., BCG 10 Anti-Tuberculosis Vaccine, Powder and solvent for suspension for intradermal injection Vaccinum tuberculosis (BCG) cryodesiccatum

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  7. Stivarga 40 mg film-coated tablets

    Istituto Gentili S.r.l.

    grade 1, 2 and 3 meningioma

    phase 2 small molecule active

    1 trial

  8. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  9. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  10. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  11. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  12. Temozolomide SUN 5 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide SUN 20 mg hard capsules, DC-VACCINE_IRSTIRCCS, Temozolomide SUN 100 mg hard capsules

    Istituto Gentili S.r.l.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  13. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  14. Trimeton 10 mg/1 ml soluzione iniettabile, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Gazyvaro 1,000 mg concentrate for solution for infusion., TACHIPIRINA 500 mg compresse, MEDROL 16 mg compresse, CORTRIUM 40 mg/2 ml polvere e solvente per soluzione iniettabile

    Istituto Gentili S.r.l.

    Primary Membranous Nephropathy

    phase 2 small molecule active

    1 trial

  15. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

  16. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  17. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  18. A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

    Laboratorios Tillomed Spain S.L.U

    Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps

    phase 1 other active

    1 trial

  19. A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.

    Lacuna Pharma Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  20. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  21. An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device

    Laboratorios Tillomed Spain S.L.U

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  22. Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Diabetes

    phase 1 other active

    1 trial

  23. Bioequivalence clinical trial of two formulations of linagliptin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  24. Bioequivalence clinical trial of two formulations of bilastine.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources